ArticleLeukemia research reports2023

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML.

Brian A Jonas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.